Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 78-86

  Bonomi, Philip ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PLACEBO; PRINOMASTAT; TANOMASTAT;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; METASTASIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 0036118399     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31528     Document Type: Article

References (38)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Final results of a phase III trial in regionally advanced unresectable non-small cell lung cancer
3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer
4. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
5. The hallmarks of cancer
6. Changing views of the role of matrix metalloproteinases in metastasis
7. ECM and cell surface proteolysis: Regulating cellular ecology
8. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
9. Matrix metalloproteinases and metastasis
10. Preclinical and clinical studies of MMP inhibitors in cancer
11. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer
12. Matrix metalloproteinases, biologic activity and clinical implications
13. Development of matrix metalloproteinase inhibitors in cancer therapy
14. Stimulation of matrix metalloproteinase production by recombinant matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
15. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in broncho-pulmonary and breast lesions
16. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type metalloproteinase (MT-MMP) and with lymph node metastases
17. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer
18. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses
19. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer
20. Expression of urokinase-type plasminogen activator, stromelysin I, stromelysin 3, and matrilysin genes in lung carcinomas
21. Overexpression of matrix metalloproteinases predicts unfavorable outcome in early-stage non-small cell lung cancer
22. TIMP 1 and adverse prognosis in non-small cell lung cancer
23. Over expression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer
24. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients
25. Serum matrix metalloproteinases - 2-9 And tissue inhibitors of metalloproteinases 1-2 in lung cancer - TIMP-1 as a prognostic marker
26. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
27. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung cancer
28. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases
29. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study
30. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung cancer
31. Molecular staging for operable non-small cell lung cancer
32. Metalloproteinase-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
33. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase 9 (MMP-9) in human breast cancer cells
34. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC and EORTC study
35. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer
36. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinoma
37. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer
38. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study